Cargando…
(212)Pb: Production Approaches and Targeted Therapy Applications
Over the last decade, targeted alpha therapy has demonstrated its high effectiveness in treating various oncological diseases. Lead-212, with a convenient half-life of 10.64 h, and daughter alpha-emitter short-lived (212)Bi (T(1/2) = 1 h), provides the possibility for the synthesis and purification...
Autores principales: | Kokov, Konstantin V., Egorova, Bayirta V., German, Marina N., Klabukov, Ilya D., Krasheninnikov, Michael E., Larkin-Kondrov, Antonius A., Makoveeva, Kseniya A., Ovchinnikov, Michael V., Sidorova, Maria V., Chuvilin, Dmitry Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777968/ https://www.ncbi.nlm.nih.gov/pubmed/35057083 http://dx.doi.org/10.3390/pharmaceutics14010189 |
Ejemplares similares
-
Search of ligands suitable for (212)Pb/(212)Bi in vivo generators
por: Bartoś, Barbara, et al.
Publicado: (2012) -
Mesenchymal stromal cell therapy alone does not lead to complete restoration of skin parameters in diabetic foot patients within a 3-year follow-up period
por: Maksimova, Nadezhda V., et al.
Publicado: (2022) -
Production, purification, and radiolabeling of the (203)Pb/(212)Pb theranostic pair
por: McNeil, Brooke L., et al.
Publicado: (2021) -
Misdiagnosis of diabetic foot ulcer in patients with undiagnosed skin malignancies
por: Lyundup, Alexey V., et al.
Publicado: (2021) -
Optimized production, purification, and radiolabeling of the (203)Pb/(212)Pb theranostic pair for nuclear medicine
por: McNeil, Brooke L., et al.
Publicado: (2023)